Apollo Global Management in talks to acquire Johnson & Johnson's orthopedics unit for $20 billion
Summary · in our words
Apollo Global Management is negotiating the acquisition of Johnson & Johnson's orthopedics division for $20 billion. The transaction would represent a major divestment by J&J as it reshapes its portfolio. Apollo, a global alternative asset manager, would add a significant medical device operation to its holdings through this deal. The orthopedics unit generates substantial revenue within J&J's medical devices segment.
Apollo Global Management is in negotiations to acquire Johnson & Johnson's orthopedics division for $20 billion, representing one of the larger carve-out transactions in the medical device space. For J&J, the divestment fits a broader portfolio reshaping effort. The non-obvious dynamic here is that conglomerate structures in healthcare tend to trade at a discount to pure-play peers in public markets, so separating the orthopedics unit under private ownership could unlock value that was suppressed inside J&J's diversified reporting structure, which is precisely the arbitrage private equity firms pursue in regulated, cash-generative sectors.
Not investment advice.
The headline and data come from Investing.com TR. The summary and analysis are Mergen's own; the full article text is not republished here.